Pressmeddelande -

Daewoong to distribute Medivir’s Xerclear™ in South Korea

Huddinge, Sweden, August 24, 2010 - Medivir AB (Sweden) today announced it has appointed Daewoong Pharmaceutical Co. Ltd. as its exclusive distributor for Xerclear™ in South Korea. Under the terms of the agreement, Daewoong will be responsible for obtaining the regulatory approvals, and for marketing, sales and distribution of Medivir’s cold sore product in the territory. In consideration of the rights granted to Daewoong, Medivir will receive upfront and milestone payments and royalties on sales according to a profit sharing scheme.

“We are pleased to announce this collaboration and to have Daewoong as our partner for Xerclear™ in South Korea”, said Ron Long, CEO of Medivir AB, and continued, “We recently initiated a collaboration with Daewoong around MIV-210 and the Xerclear™ distribution agreement further strengthens the relationship between our companies”.

“Medivir is an ideal partner for us and Xerclear™ is a perfect fit for our portfolio, providing us the excellent opportunity to offer health care professionals, care providers and patients its considerable benefits. We believe there will be a substantial market opportunity in South Korea for this topical product for the treatment of recurrent herpes labialis”, concluded Dr. Jong-Wook Lee, President and CEO, Daewoong Pharmaceutical Co. Ltd.

About Xerclear™

Xerclear™ (Xerese™ in the USA) – Medivir’s first pharmaceutical product – is a patented combination of 5% acyclovir and 1% hydrocortisone in Medivir’s proprietary cream formulation for the topical treatment of recurrent herpes labialis (cold sores). The indication text as approved by FDA, states “Xerclear™ is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolecents (12 years of age and older)”. Xerclear™ is the first topical product that in controlled clinical trials has been shown to significantly (P<0.0001 vs. placebo) reduce the development of ulcerative lesions during a cold sore episode.

The product is approved by the US FDA (trademark "Xerese™") and in Europe (trademark "Xerclear™") and will be marketed by Meda Pharma in North America and by GlaxoSmithKline (under its own consumer health brands) in Europe and a number of key markets. Medivir intends to establish further partnerships for Xerclear™ outside Sweden and Finland, where Medivir markets and sells the product today on prescription only basis.

About cold sores

Recurrent herpes labialis (cold sores) is a common infection that affects one-third of the population in the Western world resulting in around 600 million episodes per year with 57 million people having 3 or more episodes per year. The great majority of cases are caused by herpes simplex virus type 1 (HSV-1). Unlike most viruses, the cold sore virus is not completely eliminated by the body’s immune response. Instead it establishes a chronic, latent and life-long infection in sensory ganglia. At a later date, the virus may be reactivated and travel back to the skin – often around the mouth and nose – to trigger a clinical episode of recurrent herpes labialis. The virus is reactivated by factors like sunlight and stress.

Products based on antiviral substances such as aciclovir, penciclovir, famciclovir and valaciclovir are the most commonly used treatment options and to date no other combination product than Xerclear™/Xerese™ is available. The market for topical treatment of herpes infections in South Korea is estimated at USD 5 million, and in the USA and Europe at USD 230 million and USD 170 million, respectively.

About Daewoong Pharmaceutical Co. Ltd.

Daewoong Pharmaceutical Co. Ltd. is a leading Korean pharmaceutical company with annual turnover of nearly $605 million U.S. in 2009. Daewoong Pharmaceutical Co. Ltd. was ranked first in the South Korean pharmaceutical market in terms of requested reimbursement totals, according to Health Insurance Review Agency (HIRA). Daewoong has expanded global business operations throughout Asia and is currently developing strategies for the global market.

Daewoong Pharmaceutical Co. Ltd. engages in the research, development, manufacturing and marketing of healthcare products. It provides a full spectrum of healthcare products for various therapeutic areas that include infectious diseases, cardiovascular diseases, metabolic disorders, disorder of central nervous system, digestive disorders, oncology and vaccines.

Daewoong's R&D activity explores a broad spectrum of innovative approaches and has developed new products in key therapeutic area such as EGF for Mucositis and Wounds and WP05195 for Neuropathic Pain.

In particular, Daewoong Pharmaceutical Co. Ltd. has made numerous successful partnerships with multinational pharmaceutical companies launching many blockbuster products on the Korean market, and its strong growth is attributable to its dedication to excellence in sales and marketing, which is backed by a comprehensive portfolio of both innovative and generic prescription drugs.

For more information on Daewoong Pharmaceutical Co. Ltd., please see the company

website: www.daewoong.co.kr

About Medivir  

Based on its world class expertise in protease and polymerase inhibition technology, Medivir develops drugs with primary focus on infectious diseases. Its objective is to become a sustainable and profitable speciality pharmaceutical company with a strong research base. 

Medivir was listed on the Stockholm Stock Exchange in 1996 and at the end of 2009 the company had 85 employees.

For more information on Xerclear™, please contact;

Eva Arlander, VP Medivir Pharma, at +46 702 556 855

Johan Inborr, Head of Business Development Medivir Pharma, at +46 708 853 893

 

For financial and IR information, please contact;

Rein Piir, CFO & VP Investor Relations, Medivir, at  +46 708 537 292

 

For general information, please visit;

www.medivir.se

Ämnen

  • Vetenskap, teknik

Kategorier

  • xerclear
  • xerese
  • daewoong
  • cold sores
  • herpes
  • herpes labialis
  • medivir
  • munherpes

About Medivir  

Based on its world class expertise in protease and polymerase inhibition technology, Medivir develops drugs with primary focus on infectious diseases. Its objective is to become a sustainable and profitable speciality pharmaceutical company with a strong research base. 

Medivir was listed on the Stockholm Stock Exchange in 1996 and at the end of 2009 the company had 85 employees.

Media Content Panel
Xerclear - produktbild
Licens:
Medieanvändning
Ladda ner
Media Content Panel
Medivir introduction
Spela filmen
Medivir introduction
Licens:
Medieanvändning
Filformat:
.mp4
Videolängd:
1:03
Ladda ner
Media Content Panel
Introduction to cold sores
Spela filmen
Introduction to cold sores
Licens:
Medieanvändning
Filformat:
.mp4
Videolängd:
1:44
Ladda ner
Media Content Panel
Daewoong to distribute Medivir’s Xerclear™ in South Korea
Daewoong to distribute Medivir’s Xerclear™ in South Korea
Licens:
Medieanvändning
Filformat:
.pdf
Ladda ner
Media Content Panel
XereseTM / XerclearTM poster presentation at ICAAC, Sept 2009
XereseTM / XerclearTM poster presentation at ICAAC, Sept 2009
Licens:
Medieanvändning
Filformat:
.pdf
Ladda ner
Media Content Panel
Daewoong to distribute Medivir’s Xerclear™ in South Korea
Licens:
Medieanvändning
Filformat:
.doc
Ladda ner

Relaterat innehåll

Medivir partners with Meda to commercialize Xerese™ (Lipsovir®) in North America

Huddinge, Sweden, 15 February, 2010 - Medivir AB and Meda AB today announced an agreement for the commercialization of Medivir’s cold sore product Xerese™ (formerly Lipsovir®) in the United States, Canada and Mexico. For the exclusive rights, Meda will pay USD 5 million in up-front and pre-launch milestones and double-digit royalties on sales to Medivir .

A new dual action treatment can stop cold sores - Xerclear launched today

Over two million Swedish people are regularly affected by cold sores.1 The problem is characterized by lesions, vesicles and tenderness. Xerclear—the first and only cream with a label that states it can prevent both the incidence of cold sores and shorten healing times if cold sores appear despite treatment—is now being launched.(2) Xerclear is available on prescription.

Medivir - Winner of Sweden BIO Award 2010

Medivir’s CEO Ron Long received the SwedenBIO Award 2010 from research and further education minister Tobias Krantz at life sciences industry organization SwedenBIO’s annual conference in Stockholm. Medivir won the award for all the successes the company achieved in 2009.

Medivir appoints Luxembourg Pharmaceuticals as distributor for Xerclear™ in Israel

Medivir AB (OMX: MVIR), the research-based speciality pharmaceutical company focused on infectious diseases, is today pleased to announce the appointment of Luxembourg Pharmaceuticals Ltd, as the exclusive distributor for Xerclear™, Medivir’s marketed and innovative treatment for recurrent cold sores, in Israel and the Palestinian Authority.

Medivir receives USD 45 million from Meda for North American rights for Xerese™

Huddinge, Sweden - Medivir AB (OMX: MVIR) today announced that it has renegotiated the terms of its commercial partnership with Meda (OMX: MEDA A) for Xerese™, its unique marketed product for cold sores (herpes labialis). Meda launched the product in the US in February 2011 and Medivir currently receives a mid-teens royalty on Meda’s sales in this market.